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Preeclampsia is a common disorder of 
pregnancy resulting in increased blood 
pressure and end organ effects. The 
pathogenesis of preeclampsia is multi-
factorial. Arginine vasopressin (AVP) is 
increased in preeclampsia, and the 
chronic infusion of AVP throughout 
gestation has previously been shown to 
be sufficient to produce a phenotype of 
preeclampsia in C57BL/6J mice 
representative of some of the 
cardiovascular and renal events seen in 
humans. Alterations in T-helper cell 
populations and their effector cytokines 
are also known to occur in 
preeclampsia. Therefore, we proposed 
that the increased secretion of AVP may 
be responsible for the immune changes 
that occur in preeclampsia. We also 
hypothesized that known 
pharmacological AVP antagonist, 
vaptans, may be able to reverse the 
effects of AVP infusion. Using our 
previously published AVP infusion 
model for preeclampsia, we compared 
saline controls to mice and their 
offspring infused with AVP with or 
without an AVP receptor antagonist 
vaptan. AVP infusion throughout 
pregnancy in mice resulted in decreased 
anti-inflammatory cytokines IL-4 and IL-
10 in the maternal kidneys and fetal 
kidneys, while it increased pro-
inflammatory cytokines IFN-ɣ in 
maternal plasma and IL-17 in the 
placenta and amniotic fluid. Specifically 
blocking AVPR-2 increased production 
of IL-4 and IL-10 in maternal and fetal 
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kidneys, increasing the anti-
inflammatory response. Interestingly, 
correction of IL-4 in the placenta 
required blockade of both AVPR-1a/2 
with conivaptan. Proinflammatory 
marker IL-17 levels in the placenta were 
corrected by blocking AVPR-1a with 
relcovaptan, indicating that V1a may be 
responsible in the placenta for 
proinflammatory IL-17 production. 
Overall, the data seem to suggest that 
AVPR-1a plays a more dominant role in 
increasing pro-inflammatory markers, 
while AVPR2 plays more of a role in 
decreasing anti-inflammatory markers in 
preeclampsia. These results also 
support the ability of AVP to induce the 
immunological changes seen in 
preeclampsia. 
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